Infectious diseases (London, England) · 2026
Prevalence of acute kidney injury in Staphylococcus aureus bacteraemia treated with cloxacillin: a retrospective cohort study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hagstrand Aldman Malin, Sunnerhagen Torgny, Rasmussen Magnus, Påhlman Lisa I
Аннотация
BACKGROUND: Preliminary results from the SNAP trial presented at ESCMID Global 2025 reported a high incidence (19.8%) of acute kidney injury (AKI) in patients treated with (flu)cloxacillin for Staphylococcus aureus bacteraemia (SAB).
OBJECTIVE: In Sweden, cloxacillin is used at lower daily doses, and the risk of nephrotoxicity has not been assessed in this setting.
METHODS: We retrospectively evaluated renal outcomes in SAB patients with cloxacillin treatment. Patients on chronic dialysis or lacking creatinine measurements during treatment were excluded. AKI was defined as per the SNAP criteria. Long-term renal function was evaluated using follow-up creatinine values up to 12 months post-treatment.
RESULTS: Of 275 included patients, 13.8% had pre-existing renal impairment. Cloxacillin doses in median were 8 g/24h (IQR 6-8). AKI occurred in 35 patients (12.8%), of which 26 had AKI stage 1, four had AKI stage 2 and five had AKI stage 3. AKI was associated with higher Pitt Bacteraemia Score, pre-existing renal disease and high-dose cloxacillin. Among survivors (n = 239), only four patients (1.3%) had verified persistent renal impairment at follow-up.
CONCLUSION: Compared to results from the SNAP trial, cloxacillin was associated with a lower incidence of AKI that was mostly mild and transient. Persistent renal impairment was rare. The data suggest that cloxacillin at lower dosing levels is less nephrotoxic and potentially safe to use.
OBJECTIVE: In Sweden, cloxacillin is used at lower daily doses, and the risk of nephrotoxicity has not been assessed in this setting.
METHODS: We retrospectively evaluated renal outcomes in SAB patients with cloxacillin treatment. Patients on chronic dialysis or lacking creatinine measurements during treatment were excluded. AKI was defined as per the SNAP criteria. Long-term renal function was evaluated using follow-up creatinine values up to 12 months post-treatment.
RESULTS: Of 275 included patients, 13.8% had pre-existing renal impairment. Cloxacillin doses in median were 8 g/24h (IQR 6-8). AKI occurred in 35 patients (12.8%), of which 26 had AKI stage 1, four had AKI stage 2 and five had AKI stage 3. AKI was associated with higher Pitt Bacteraemia Score, pre-existing renal disease and high-dose cloxacillin. Among survivors (n = 239), only four patients (1.3%) had verified persistent renal impairment at follow-up.
CONCLUSION: Compared to results from the SNAP trial, cloxacillin was associated with a lower incidence of AKI that was mostly mild and transient. Persistent renal impairment was rare. The data suggest that cloxacillin at lower dosing levels is less nephrotoxic and potentially safe to use.